ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients

Atezolizumab, an immune checkpoint inhibitor, has been approved for use in clinical practice in non-small cell lung cancer (NSCLC) patients, but potential biomarkers for response stratification still need further screening. In the present study, a total of 399 patients with high-quality ctDNA profil...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jun, Zhang, Yanwei, Lou, Yuqing, Yan, Bo, Zou, Benkun, Hu, Minjuan, Wang, Yanan, Chen, Ya, Yang, Zhengyu, Wang, Huimin, Zhang, Wei, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452871/
https://www.ncbi.nlm.nih.gov/pubmed/34557222
http://dx.doi.org/10.3389/fgene.2021.723670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452871/
https://www.ncbi.nlm.nih.gov/pubmed/34557222
http://dx.doi.org/10.3389/fgene.2021.723670

Ejemplares similares